Hudson Value Partners LLC Acquires Shares of 759 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Hudson Value Partners LLC acquired 759 shares of Regeneron Pharmaceuticals, valued at approximately $398,000, during the 2nd quarter.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, surpassing estimates by $4.46, alongside a revenue of $3.68 billion.
• Analysts have mixed ratings on the stock, with a consensus price target of $817.67 and a general rating of "Moderate Buy."

Hudson Value Partners LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 759 shares of the biopharmaceutical company's stock, valued at approximately $398,000.

Other large investors have also recently added to or reduced their stakes in the company. Marietta Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after buying an additional 2,501 shares during the period. Sepio Capital LP increased its stake in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after buying an additional 842 shares during the period. Founders Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after buying an additional 538 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares during the period. Finally, KBC Group NV increased its stake in Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after buying an additional 12,793 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on REGN. Morgan Stanley restated an "overweight" rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Finally, Citigroup restated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Trading Up 6.7%

Shares of REGN stock opened at $599.94 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,045.95. The stock has a market cap of $63.59 billion, a price-to-earnings ratio of 15.12, a P/E/G ratio of 1.79 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a fifty day moving average of $570.67 and a 200-day moving average of $568.93.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the prior year, the company posted $11.56 EPS. The business's revenue was up 3.6% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.